Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Cash from Operations (2022 - 2025)

Historic Cash from Operations for Century Therapeutics (IPSC) over the last 4 years, with Q3 2025 value amounting to -$25.6 million.

  • Century Therapeutics' Cash from Operations rose 969.93% to -$25.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$112.0 million, marking a year-over-year increase of 10.7%. This contributed to the annual value of -$110.1 million for FY2024, which is 2466.04% down from last year.
  • Latest data reveals that Century Therapeutics reported Cash from Operations of -$25.6 million as of Q3 2025, which was up 969.93% from -$27.6 million recorded in Q2 2025.
  • Over the past 5 years, Century Therapeutics' Cash from Operations peaked at $86.8 million during Q1 2022, and registered a low of -$34.6 million during Q1 2025.
  • Over the past 4 years, Century Therapeutics' median Cash from Operations value was -$25.6 million (recorded in 2025), while the average stood at -$18.1 million.
  • Over the last 5 years, Century Therapeutics' Cash from Operations had its largest YoY gain of 4368.76% in 2023, and its largest YoY loss of 13368.07% in 2023.
  • Over the past 4 years, Century Therapeutics' Cash from Operations (Quarter) stood at -$22.9 million in 2022, then fell by 14.51% to -$26.2 million in 2023, then increased by 7.65% to -$24.2 million in 2024, then decreased by 5.62% to -$25.6 million in 2025.
  • Its Cash from Operations was -$25.6 million in Q3 2025, compared to -$27.6 million in Q2 2025 and -$34.6 million in Q1 2025.